Abstract
The production of the analgesic peptide HCRG21 for medical use is restricted by a number of limitations in the technology. The optimal biotechnological method scalable to industrial has been developed based on the production of a fusion protein containing a special leader, His-tag, and Smt3 sequence upstream in the peptide sequence. The resulting peptide shared its inhibitory activity to TRPV1 ion channel identical to the published early.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
